UPDATE 1-FDA panel rejects Merck claim that Vytorin cuts heart risk

Dec 14 (Reuters) - Merck & Co should not be allowed to claim that its cholesterol-lowering drug Vytorin reduces the risk of heart attacks and strokes in patients with coronary heart disease, an advisory committee to the U.S. Food and Drug Administration concluded on Monday.